Highlights Ocugen, Inc. Börse Stuttgart

Equities

2H51

US67577C1053

Real-time Estimate Tradegate Other stock markets 09:31:41 2024-07-17 EDT			5-day change	1st Jan Change
1.705 ^EUR	-3.23%		+7.50%	+220.95%

07-01	Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Small Cap Completeness Index	CI
07-01	Ocugen, Inc.(NasdaqCM:OCGN) added to Russell Microcap Growth Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Steady Premarket Friday	06-21	MT
Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate	06-21	MT
Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease	06-21	CI
Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400?First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication	06-20	CI
Sector Update: Health Care Stocks Advance Friday Afternoon	05-31	MT
Ocugen Gets Recommendation For Dose Escalation in Eye Disease Trial; Shares Climb	05-31	MT
Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410	05-31	CI
Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study	05-15	MT
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy	05-15	CI
Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	05-14	CI
Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024	04-29	CI
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration	04-19	MT
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy	04-19	CI
Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	04-16	CI
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for Ocu400?Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication	04-10	CI
Ocugen Gets FDA Clearance for IND Amendment for OCU400	04-08	DJ
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial	04-08	CI
Sector Update: Health Care Stocks Rise Late Afternoon	04-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ocugen, Inc. Börse Stuttgart

Equities

2H51

US67577C1053

Highlights

Filters